Nuvectis Pharma, Inc. (NVCT)
21.08
+0.06
(+0.29%)
USD |
NASDAQ |
Nov 10, 16:00
21.19
+0.11
(+0.52%)
After-Hours: 20:00
Nuvectis Pharma EPS Diluted (Quarterly) : -1.020 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -1.020 |
| June 30, 2026 | -0.299 |
| March 31, 2026 | -0.2584 |
| December 31, 2025 | -0.2848 |
| September 30, 2025 | -0.4354 |
| June 30, 2025 | -0.2964 |
| March 31, 2025 | -0.2674 |
| December 31, 2024 | -0.3205 |
| September 30, 2024 | -0.241 |
| June 30, 2024 | -0.262 |
| March 31, 2024 | -0.2519 |
| December 31, 2023 | -0.3802 |
| Date | Value |
|---|---|
| September 30, 2023 | -0.3652 |
| June 30, 2023 | -0.3761 |
| March 31, 2023 | -0.275 |
| December 31, 2022 | -0.4573 |
| September 30, 2022 | -0.4183 |
| June 30, 2022 | -0.2806 |
| March 31, 2022 | -0.3213 |
| December 31, 2021 | -0.1778 |
| September 30, 2021 | -0.367 |
| June 30, 2021 | -0.4669 |
| March 31, 2021 | -0.0018 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Opus Genetics, Inc. | -0.4565 |
| Faeth Therapeutics, Inc. | -0.7894 |
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | -0.0232 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -30.07M |
| Total Expenses (Quarterly) | 30.07M |
| Enterprise Value | 400.56M |
| Earnings Yield | -8.84% |
| Normalized Earnings Yield | -8.836 |